Concord Biotech Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Concord Biotech Ltd. on BSE

Load latest

Concord Biotech Ltd.

22 Feb 2025

1688.60

0.16%

Company Update

Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015.

pdf

Concord Biotech Ltd.

21 Feb 2025

1688.60

0.16%

Earnings Call

Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Enclosed herewith the transcripts of Q3/9M-FY25 Earning Call held on the 14th February, 2025

pdf

Concord Biotech Ltd.

20 Feb 2025

1688.60

0.16%

Company Update

Concord Biotech Ltd - 543960 - Intimation About Completion Of Inspection By Ministry Of Food And …

BSE India

Enclosed herewith Intimation regarding successful completion of Inspection by Ministry of Food and Drug Safety (MFDS) at Manufacturing Unit-1 situated at Dholka.

pdf

Concord Biotech Ltd.

15 Feb 2025

1688.60

0.16%

Company Update

Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Please Find enclosed herewith extracts of Unaudited Standalone and consolidated Financial Results for the Third quarter and Nine Months ended on December 31, 2024, published in Financial Express newspaper on 15th February 2025.

pdf

Concord Biotech Ltd.

14 Feb 2025

1688.60

0.16%

Earnings Call

Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

BSE India

Pursuant to the provision of Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, and further to our intimation dated January 31, 2025 to the Stock exchanges regarding Earning call in respect of the unaudited (Standalone and Consolidated) Financial Results of the company for third quarter and Nine Months ended December 31, 2024, we wish to inform that the said Earning Call was held today at 04:00 PM (IST).

pdf

Concord Biotech Ltd.

14 Feb 2025

1688.60

0.16%

Investor Presentation

Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Investor Presentation

BSE India

Investor presentation on Financial results for the Third Quarter and nine months ended on 31st December,2024, is enclosed herewith for record.

pdf

Concord Biotech Ltd.

13 Feb 2025

1688.60

0.16%

Corp. Note

Concord Biotech Ltd - 543960 - Integrated Filing (Financial)

BSE India

Integrated filling of financial results for the quarter and nine months period ended on 31st December, 2024

pdf

Concord Biotech Ltd.

13 Feb 2025

1688.60

0.16%

Result

Concord Biotech Ltd - 543960 - Financial Results For The Period Ended 31 December 2024

BSE India

Pursuant to Regulation 30 and 33 of SEBI (LODR) regulations, 2015, as amended from time to time. We enclosed herewith Unaudited Standalone and Consolidated Financial results of the company for the Third quarter and nine months ended on December 31, 2024, along with the limited review reports with Unmodified Opinion Issued by M/s. BSR & Co. LLP, The statutory Auditor.

pdf

Concord Biotech Ltd.

13 Feb 2025

1688.60

0.16%

Board Meeting

Concord Biotech Ltd - 543960 - Board Meeting Outcome for Financial Results For The Period Ended …

BSE India

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, we enclose herewith the Unaudited Standalone and Consolidated Financial Results of the Company for the Third quarter and Nine months ended on December 31, 2024, along with the Limited Review Report with Unmodified Opinion issued by M/s. BSR & Co. LLP, the Statutory auditors

pdf

Concord Biotech Ltd.

31 Jan 2025

1688.60

0.16%

Company Update

Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, read with Para A of Schedule III thereto, We wish to inform you that the Company has arranged Earnings Call with Investor/Analyst (Participants) to discuss the Unaudited Standalone and Consolidated Financial Results of the Company for the third quarter and nine months ended 31st December, 2024, scheduled on Friday, 14th February, 2025 at 04:00 P.M. IST.

pdf